Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.1K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.1K
Language Development01:22

Language Development

918
Children master language quickly and with relative ease, supported by both biological predisposition and reinforcement. B. F. Skinner (1957) proposed that language is learned through reinforcement, while Noam Chomsky (1965) argued that language acquisition mechanisms are biologically determined.
The critical period for language acquisition suggests that the ability to acquire language is at its peak early in life. As people age, this proficiency decreases. Language development begins very...
918
Development of Immunocompetence01:22

Development of Immunocompetence

906
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
906
Development of the Heart01:27

Development of the Heart

2.5K
The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyano-modulated Zn(II)-Schiff base complexes for lysosome-targeted fluorescence imaging and pH-responsive camptothecin delivery.

International journal of pharmaceutics: X·2026
Same author

Comparison of Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single-Center Real-World Experience.

EJHaem·2026
Same author

Targeting the ELF1/EGFR/ERK positive feedback loop overcomes resistance to androgen receptor inhibition in AR-Vs positive prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Cellular and signaling mechanisms of cyantraniliprole toxicity in the nontarget organism Bombyx mori.

Journal of hazardous materials·2026
Same author

A Novel TUBB1 p.E158del Variant Causes Inherited Macrothrombocytopenia via Impaired Microtubule Assembly.

International journal of laboratory hematology·2026
Same author

The Key Diagnostic Role of Morphology: Rheumatoid Arthritis With MYH9-Related Disorder.

International journal of laboratory hematology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 5, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

New developments in immunotherapy for lymphoma.

Benjamin Heyman1, Yiping Yang1,2

  • 1Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine.

Cancer Biology & Medicine
|September 11, 2018
PubMed
Summary

Immunotherapies for lymphoma, including CAR T-cells and bispecific antibodies, have revolutionized treatment. This review focuses on promising clinical developments and strategies for improving these advanced lymphoma therapies.

Keywords:
CAR-T cellsbispecific antibodiesimmune checkpoint blockade

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

Related Experiment Videos

Last Updated: Feb 5, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Immunotherapy has transformed lymphoma treatment over the past decades.
  • Rituximab marked a significant advancement as the first immunotherapy for B-cell non-Hodgkin lymphoma.
  • Numerous novel immunotherapeutic strategies are now available for lymphoma care.

Purpose of the Study:

  • To review promising immunotherapeutic approaches for lymphoma currently in clinical development.
  • To focus on clinical trial data and strategies for enhancing treatment efficacy.
  • To provide an overview of the evolving landscape of lymphoma immunotherapy.

Main Methods:

  • Review of recent clinical trials and studies on novel immunotherapies for lymphoma.
  • Analysis of key immunotherapeutic classes: CAR T-cells, bispecific antibodies, immune checkpoint inhibitors, and vaccines.
  • Discussion of challenges and considerations for novel therapies, including timing, patient selection, duration, toxicity, and cost.

Main Results:

  • Significant progress has been made in developing immunotherapies beyond rituximab.
  • Chimeric antigen receptor T-cells, bispecific antibodies, immune checkpoint inhibitors, and vaccines show considerable promise.
  • Ongoing research is refining patient selection, treatment protocols, and managing toxicity for these therapies.

Conclusions:

  • The field of lymphoma immunotherapy is rapidly advancing with innovative approaches.
  • Careful consideration of treatment parameters and patient factors is crucial for optimizing outcomes.
  • Further research and clinical trials are essential to improve the effectiveness and accessibility of these life-saving treatments.